Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Casdozokitug |
| Trade Name | |
| Synonyms | SRF-388|SRF 388|SRF388|CHS-388|CHS388|CHS 388|Casdozo |
| Drug Descriptions |
Casdozokitug (CHS-388) is a monoclonal antibody that binds to interleukin 27 (IL27) and inhibits downstream signaling, which potentially modulates immune response and inhibits tumor growth (Journal for ImmunoTherapy of Cancer Nov 2019, 7 (Suppl 1) 283, Abs nr: P805; Immuno-Oncology and Technology 24 (2024):100783). |
| DrugClasses | |
| CAS Registry Number | 2643331-37-5 |
| NCIT ID | C174410 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Bevacizumab + Casdozokitug | Atezolizumab Bevacizumab Casdozokitug | 0 | 1 |
| Bevacizumab + Casdozokitug + Toripalimab-tpzi | Bevacizumab Casdozokitug Toripalimab-tpzi | 0 | 1 |
| Casdozokitug | Casdozokitug | 0 | 1 |
| Casdozokitug + Pembrolizumab | Casdozokitug Pembrolizumab | 0 | 1 |
| Casdozokitug + Toripalimab-tpzi | Casdozokitug Toripalimab-tpzi | 0 | 1 |